FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

Morra R, Lebray P, Ingiliz P, Ngo Y, Munteanu M …

MeSH — NLM indexing Aspartate Aminotransferases / blood Biomarkers / blood Hepatitis C, Chronic / complications Humans Liver Cirrhosis / blood Liver Cirrhosis / diagnosis Liver Cirrhosis / virology Platelet Count Prognosis

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Fibrotest Actitest Letter Our Group France

Authors (7)

Citation

Morra R, Lebray P, Ingiliz P, Ngo Y, Munteanu M, Ratziu V, et al. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology. 2008;47(1):353-4; author reply 354-6. doi:10.1002/hep.22046.

Identifiers

DOI: 10.1002/hep.22046
PMID: 18161711

Tests

Liver diseases

Liver injuries

Comparisons

Subjects

Patient populations

Region

FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.

More by Morra R

Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.

FibroMAX: towards a new universal biomarker of liver disease?

More on the same topic

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Toward non-invasive assessment strategies in autoimmune hepatitis.

Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.

Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts.

Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.